![](/media/13098/agi-opening.png?crop=0,0,0,0.0004520795660035372&cropmode=percentage&width=1200&height=900&rnd=133613688900000000)
US$100 million Series C investment in Biofourmis Holdings Pte. Ltd. led by SoftBank Vision Fund II
![](/media/3550/weekly-deal-summaries-img1.jpg?anchor=center&mode=crop&width=1200&height=900&rnd=132006800310000000)
Allen & Gledhill advised SoftBank Vision Fund II, as transaction counsel, which led the US$100 million Series C investment (“Investment”) in Biofourmis Holdings Pte. Ltd., a health start-up that combines artificial intelligence-based data analytics and biosensors to monitor the progress of medical treatments.
The Investment is a significant milestone in the growth of Biofourmis which develops artificial intelligence-powered digital therapeutic solutions to enhance conventional health services.
Advising SoftBank Vision Fund II were Allen & Gledhill Partners Christian Chin, Eugene Ho and Tan Kai Liang.